AirXpanders (ASX:AXP) has achieved 100 per cent successful expansion and exchange of breast impants in 50 women who had mastectomies.
It comes as the medical device company’s fifth prospective trial also confirmed doctor and patient satisfaction, ease of use and convenience with its AeroForm Tissue Expander System.
The company presented these findings at the 86th Plastic Surgery annual scientific meeting in Orlando.
AeroForm offers a needle free alternative for women who choose to have reconstructive surgery after a mastectomy.
Shares in AirXpanders (ASX:AXP) are trading 0.68 per cent higher to 74 cents.